Search
Terlipressin
go.drugbank.com/drugs/DB02638ApprovedInvestigationalTerlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor.[A2601] It is a prodrug of [lypressin], or lysine vasopressin. … [L43217] As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone.
Products: HAEMOPRESSIN® 1 MG, GLYPRESSIN ® 1 MGTransient receptor potential cation channel subfamily A member 1
go.drugbank.com/bio_entities/BE0001122TargetHumansHas a relatively high Ca(2+) selectivity, with a preference for divalent over monovalent cations (Ca(2+) > Ba(2+) > Mg(2+) > NH4(+) > Li(+) > K(+)), the influx of cation into the cytoplasm leads to membrane … Has a central role in the pain response to endogenous inflammatory mediators, such as bradykinin and to a diverse array of irritants.
Polypeptides: Transient receptor potential cation channel subfamily A member 1Low affinity immunoglobulin gamma Fc region receptor III-A
go.drugbank.com/bio_entities/BE0002097TargetHumansOptimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC
Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-ASynonyms: IgG Fc receptor III-ASolifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigationalSolifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. … [L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511]
Mixtures: VESOMNİ 6 MG/0.4 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 ADET, Vesomni 6 mg/0,4 mg Tabletten mit veränderter WirkstofffreisetzungCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesZidovudine
go.drugbank.com/drugs/DB00495ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. … The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription.
Mixtures: N/A, LAVUZID® NCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesTrospium
go.drugbank.com/drugs/DB00209ApprovedInvestigationalTrospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. … [L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: TROSBIO® 30 MG, TROSBIO® 15 MGSuccinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial
go.drugbank.com/bio_entities/BE0002256TargetEnzymeHumans) and produce a new acyl-CoA. … Catalyzes the first, rate-limiting step of ketone body utilization in extrahepatic tissues, by transferring coenzyme A (CoA) from a donor thiolester species (succinyl-CoA) to an acceptor carboxylate (acetoacetate
Polypeptides: Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrialNKG2-A/NKG2-B type II integral membrane protein
go.drugbank.com/bio_entities/BE0010560TargetHumansDominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity (PubMed:12387742). … In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell
Polypeptides: NKG2-A/NKG2-B type II integral membrane proteinSynonyms: NK cell receptor A, NKG2-A/B-activating NK receptorEstradiol valerate
go.drugbank.com/drugs/DB13956ApprovedInvestigationalVet approvedEstradiol Valerate (also known as E2V) is a pro-drug ester of [DB00783], a naturally occurring hormone that circulates endogenously within the human body. … Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction
Mixtures: CYCLO PROGYNOVA N 2MG/0.15, CYCLO PROGYNOVA N 2MG/0.15Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalSunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. … These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R).
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: SUNITINIB EG, SUTENT® CAPSULAS 25 MG